Then the multiplex fluorescence staining of a panel of immune markers (CD3, CD4, CD8, FOXP3 and PDL1) and T cell receptor sequence were done in paired GC samples (prechemotherapy and postchemotherapy) from 30 stage II/III GC patients whose response to NAC were rigorously defined. The gene discussed is CD8A; the disease is gastric cancer.